24/7 Market News Snapshot 12 June, 2025 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)

June 12, 2025

DENVER, Colo., 12 June, 2025 (www.247marketnews.com) – (Nasdaq:PLRZ) are discussed in this article.
Polyrizon Ltd. (Nasdaq:PLRZ) is experiencing notable growth in its stock performance, with shares opening today at $0.838 and currently trading at $0.924, reflecting a remarkable 15.5% increase. This rise follows a previous close of $0.800, signifying robust bullish momentum in the market. Trading volume stands at 4.59 million shares, indicating heightened investor interest and market activity. Analysts suggest that a breakout above the $0.900 resistance level could catalyze further gains, while support is noted around $0.800. Investors are urged to keep a close watch on these key technical indicators, as Polyrizon continues to exhibit significant market volatility.

In conjunction with its stock market performance, Polyrizon has also announced promising results from a preclinical study of its innovative hydrogel-based Trap & Target (T&T) platform designed for intranasal drug delivery. Conducted in partnership with leading experts, the study utilized a silicone-based human nasal cast and fluorescein-traced imaging techniques, yielding over 60% preferential accumulation of the hydrogel in the middle and upper turbinates of the nasal cavity. This targeted deposition is critical for efficient central nervous system (CNS) drug delivery, which is vital for conditions requiring rapid therapeutic intervention, such as opioid overdoses and epileptic seizures.

Tomer Izraeli, CEO of Polyrizon, expressed optimism regarding the results, emphasizing the platform’s ability to achieve localized nasal delivery. The hydrogel demonstrates favorable handling characteristics and concentrated delivery prospects, reinforcing the company’s commitment to advancing therapies for acute neurological and psychiatric disorders. Polyrizon plans to validate these preclinical findings through subsequent animal studies and safety evaluations, paving the way for innovative therapeutic options through its pioneering intranasal delivery technology.

Related news for (PLRZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.